Humanized Patient-Derived Xenograft Models of Ovarian Cancer

Methods Mol Biol. 2022:2424:255-274. doi: 10.1007/978-1-0716-1956-8_17.

Abstract

In vivo modeling of cancer is a critical step in testing novel therapeutic strategies to advance patient care. Here we describe how to develop a humanized patient-derived xenograft (PDX) model of ovarian cancer that uses orthotopically transplanted patient ovarian tumors with autologous transfer of expanded tumor infiltrating T cells (TILs) as a model that can be utilized to test immunomodulating therapeutics in vivo.

Keywords: Immune checkpoint blockade; Immunotherapy; In vivo modeling; Patient-derived xenograft; T-cell expansion; Tumor infiltrating lymphocytes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinoma, Ovarian Epithelial
  • Disease Models, Animal
  • Female
  • Heterografts
  • Humans
  • Lymphocytes, Tumor-Infiltrating*
  • Ovarian Neoplasms* / therapy
  • Xenograft Model Antitumor Assays